These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23375349)

  • 1. Angiogenesis and anti-angiogenic therapy in prostate cancer.
    Mukherji D; Temraz S; Wehbe D; Shamseddine A
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
    Schweizer MT; Carducci MA
    Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment developments applied to elderly patients with advanced prostate cancer.
    Mukherji D; Pezaro CJ; Shamseddine A; De Bono JS
    Cancer Treat Rev; 2013 Oct; 39(6):578-83. PubMed ID: 23290885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging treatments in the management of castration-resistant prostate cancer.
    Shapiro D; Tareen B
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of angiogenesis inhibitors in prostate cancer.
    Aragon-Ching JB; Dahut WL
    Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab treatment of prostate cancer.
    Small AC; Oh WK
    Expert Opin Biol Ther; 2012 Sep; 12(9):1241-9. PubMed ID: 22775507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
    Ryan CJ; Lin AM; Small EJ
    Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
    Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibitors in the treatment of prostate cancer.
    Adesunloye BA; Karzai FH; Dahut WL
    Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis as a strategic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutic approaches to advanced prostate cancer.
    Armstrong AJ; Carducci MA
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):271-82. PubMed ID: 16167000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenesis: a possible treatment option for prostate cancer?
    Longoria RL; Cox MC; Figg WD
    Clin Genitourin Cancer; 2005 Dec; 4(3):197-202. PubMed ID: 16425989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving therapeutic paradigms for advanced prostate cancer.
    Ruch JM; Hussain MH
    Oncology (Williston Park); 2011 May; 25(6):496-504, 508. PubMed ID: 21717904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of metastatic castration-resistant prostate cancer: recent advances.
    Mukherji D; Eichholz A; De Bono JS
    Drugs; 2012 May; 72(8):1011-28. PubMed ID: 22621691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update in systemic therapy of urologic malignancies.
    Mooney D; Paluri R; Mehta A; Goyal J; Sonpavde G
    Postgrad Med; 2014 Jan; 126(1):44-54. PubMed ID: 24393751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.